Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial.

SP, Marso; NR, Poulter; SE, Nissen; MA, Nauck; B, Zinman; GH, Daniels; S, Pocock; WM, Steinberg; RM, Bergenstal; JF, Mann; LS, Ravn; KB, Frandsen; AC, Moses; JB, Buse

doi:10.1016/j.ahj.2013.07.012

Public

Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial.

Shared by NobleBlocks on Oct 2, 2013 • 12:00 AM UTC

Authors:

Marso SP

Poulter NR

Nissen SE

Abstract

<h4>Background</h4>Diabetes is a multisystem disorder associated with a nearly twofold excess risk for a broad range of adverse cardiovascular outcomes including coronary heart disease, stroke, and cardiovascular death. Liraglutide is a human glucagon-like peptide receptor analog approved for use in...

Discussions